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The study of rare human genetic disorders has often led to some of the most signiﬁcant advances in biomedical research. One such
example was the body of work that resulted in the identiﬁcation of the Low Density Lipoprotein-Related Protein (LRP5) as a key
regulator of bone mass. Point mutations were identiﬁed that encoded forms of LRP5 associated with very high bone mass (HBM).
HBM patients live to a normal age and do not appear to have increased susceptibility to carcinogenesis or other disease. Thus,
devising methods to mimic the molecular consequences of this mutation to treat bone diseases associated with low bone mass
is a promising avenue to pursue. Two groups of agents related to putative LRP5/6 functions are under development. One group,
the focus of this paper, is based on antagonizing the functions of putative inhibitors of Wnt signaling, Dickkopf-1 (DKK1), and
Sclerostin (SOST). Another group of reagents under development is based on the observation that LRP5 may function to control
bone mass by regulating the secretion of serotonin from the enterrochromaﬃnc e l l so ft h ed u o d e n u m .
1.Introduction
During the last decade, several groups working on the
genetics of rare human skeletal disorders observed that
mutations in what were thought to be core or regulatory
components of the Wnt/β-catenin pathway lead to dramatic
phenotypic eﬀects. These mutations were either in the
gene encoding the low density lipoprotein receptor-related
protein-5 (LRP5)o ri nag e n e( SOST) encoding a protein
(Sclerostin) that potentially binds and regulates the function
of LRP5 and its family members LRP4 and LRP6. This
work has established LRP5 as a major target for drug
development to treat osteoporosis and other bone diseases.
This paper will discuss the development of two groups of
agents designed to activate LRP5 (and the related LRP6)
signaling pathway to increase bone mass. We will ﬁrst
review the core components of the Wnt signaling pathway
to put the development of these agents into a cellular
context.
These are by no means the only agents related to the
identiﬁcation of LRP5 that are in clinical development.
One of the more interesting areas of research has centered
around the observation by Yadav and colleagues that loss
of LRP5 leads to low bone mass due to dysregulation of
serotonin synthesis from the enterochromaﬃn cells of the
duodenum [1]. Normally, LRP5 inhibits the expression of
TPH1, the rate-limiting enzyme for serotonin production
in enterochromaﬃn cells. In the absence of LRP5 in both
humans and mice, serum serotonin levels were reported to
rise and act on the HTR1B receptor in osteoblasts to inhibit
their proliferation [1, 2]. Patients and mice carrying alleles
of LRP5 associated with high bone mass are reported to have
decreased levels of serum serotonin [1, 3]. This has led to
the exciting possibility that pharmacological modulation of
serum serotonin levels could be an eﬀective treatment for
low bone mass, a possibility supported by a recent report.
More detailed discussions of this potential treatment can be
found in several recent reviews [4, 5].2 Journal of Osteoporosis
While not discounting the potential importance of
serotonin-based therapies, this paper primarily focuses on
the development of agents that potentially target LRP5, and
the related proteins LRP6 and LRP4, in the bone itself.
2. Overview of Wnt Signaling
Mammals contain 19 genes encoding Wnt ligands. Wnts
are cysteine-rich, glycosylated, and lipid-modiﬁed proteins
that are highly associated with the extracellular matrix,
particularly heparin sulfate glycoproteins [6]. Wnts can
activate several signaling cascades, including one that results
in the stabilization of β-catenin in the cytoplasm followed
by its nuclear localization [7]. Wnts initiate signaling by
binding to a member of the Frizzled family of seven
transmembrane receptors and either LRP5 or LRP6 [8–10]
(Figure 1), leading to downregulation of glycogen synthase
kinase-3 (GSK-3) activity. In the absence of Wnt ligands,
GSK-3 phosphorylates β-catenin on residues near it amino
terminalend,markingitforubiquitin-dependentproteolysis
[11]. Inactivation of GSK-3 increases β-catenin levels in the
cytosol. Recent work has also uncovered a parallel set of
signals that are initiated by activation of the Wnt receptor
complex that lead to the phosphorylation of β-catenin on
serine residues (in regions C terminal to and independent
from the GSK3 sites). Phosphorylation of these residues is
required for eﬃcient nuclear translocation [12, 13]. The
combined eﬀect of increasing levels of cytosolic β-catenin
and facilitating its translocation to the nucleus allows β-
catenin to form complexes with members of the Tcf/Lef class
of DNA binding proteins [14]. These complexes modulate
transcriptional activity of target promoters [14].
This core pathway is regulated by a large number of
extracellularandintracellularproteins.Extracellularproteins
that interact with this pathway include members of the
Dickkopf family and Sclerostin and secreted frizzled related
proteins (sFRPs) which regulate signaling at the level of
the Wnt/Frizzled/Lrp interaction [15–21]( Figure 1). In
addition, many proteins (including GBP/FRAT, axin, βTrCP,
and APC, the product of the adenomatous polyposis coli
tumor suppressor gene) control the pathway by regulating
components of the intracellular signaling pathway [9, 14].
The eﬀects of regulating GSK3 activity by Wnt sig-
naling can also directly activate the mammalian target of
rapamycin (mTOR) pathway by decreasing GSK-3-mediated
activation of the TSC2/TSC1 complex [22]. This observation
extends our understanding of the role of Wnt signaling in
cellular regulation and identiﬁes mTOR as an important
downstream aﬀector of Wnt signaling and, by extension,
a potential downstream target of Lrp5 and/or Lrp6 during
osteoblast diﬀerentiation. Activation of the mTOR pathway
by Wnt ligands is independent of β-catenin, highlighting
a signaling cascade that could explain diﬀerent phenotypes
seen when the pathway is inactivated at the level of Lrp5
and/or Lrp6 compared to inactivation of β-catenin. In
addition to the canonical pathway [14], other signaling
cascades initiated by Wnts include pathways that signal
through the Rho GTPases and calcium-dependent pathways
[23]. For more detailed descriptions of the Wnt signaling
pathway, several excellent recent reviews on the subject are
available [6–8, 24–27].
3. Overview of LRP Family Members
Although partially redundant, Lrp4, Lrp5, and Lrp6 display
clearly distinct functions. For example, Lrp6-deﬁcient mice
die at birth [28], whereas Lrp5- and Lrp4-deﬁcient mice are
viable [29], suggesting unique functions of these receptors
that cannot be compensated for by the others. While Lrp5-
deﬁcientmicedevelopanormalskeletalstructure[30],Lrp6-
deﬁcient mice exhibit long bone formation defects. These
defects are reminiscent of those observed in Wnt-7a and
Wnt-1mutantmice,indicatingapossiblelinkbetweenWnt1
or Wnt7a and Lrp6 that may not exist between these Wnts
and Lrp5 [28]. Another possibility is that the role of Lrp6
mayalsoinvolvedownregulationoftheWnt5anoncanonical
signaling pathways.
It was recently shown that Lrp6 physically interacts with
Wnt5a, but that this does not lead to phosphorylation of
Lrp6 or activation of the Wnt/β-catenin pathway. Overex-
pression of Lrp6 blocks activation of the Wnt5a-target, Rac,
and this eﬀect is dependent on intact Lrp6 extracellular
domains. Surprisingly, some Lrp6−/− birth defects were
rescuedbydeletionofWnt5a,indicatingthatthephenotypes
resulted from noncanonical Wnt gain-of-function [31].
Finally, the Wnt5a loss-of-function birth defect is consistent
with Ca2+ modulation having an antagonistic interaction
with Wnt/β-catenin signaling [32].
Similar to Lrp6, Lrp4 (a.k.a. Megf7) plays a role in limb
development [33]. Lrp4-deﬁcient mice have less severe phe-
notypes than those lacking Lrp6, but more severe than Lrp5-
deﬁcient mice. Phenotypes in Lrp4-deﬁcient mice include
a fully penetrant form of polysyndactyly and a mild and
incompletely penetrant form of craniofacial abnormalities
[34].
Detailed analysis of the functions of these receptors in
several additional tissues using several mouse models are
in progress. These include the mammary gland, where the
functions of both Lrp5 and Lrp6 are linked to mammary
progenitor cell regulation and where the proteins appear to
function in at least a partially redundant fashion and aﬀect
the levels of Wnt/β-catenin signaling within the mammary
gland [35–37]. In addition, changes in both LRP5 and LRP6
have been linked to alterations in glucose homeostasis and
lipid metabolism [38–43], although it is not certain whether
these latter functions are dependent on the Wnt/β-catenin
signaling pathway.
Recent studies have also highlighted an important unan-
swered question related to the function of LRP family
receptors in osteoblasts. Conditional deletion of β-catenin,
or activation of the pathway by either inducible expression of
a oncogenic version of β-catenin or via deletion of the Apc
gene, leads to dramatic eﬀects on osteoclastogenesis due to
altered regulation of osteoprotegerin expression [44, 45]. In
contrast, neither humans nor mice lacking LRP5 display any
apparent alteration in osteoclast diﬀerentiation or function.
There are several potential explanations for this. One is thatJournal of Osteoporosis 3
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Figure 1: The current model for the induction of stabilization of β-catenin by Wnt ligands holds that Wnt proteins bind a complex that
includes a member of the frizzled family of seven-transmembrane-spanning receptors and either LRP6 or LRP5. Several proteins have been
identiﬁed that can block this process and are associated with downregulation of Wnt signaling. These include proteins which bind to the
LRP component to prevent association of Wnt ligands with the LRPs (Dkk1 and Sost). In addition, secreted frizzled related proteins (sFRPs)
also can block signaling by binding directly to Wnt ligands and potentially interfering with their ability to engage the receptor complex.
the functions of LRP5 within the duodenum may play a pre-
dominantrole[1].ItisalsopossiblethatLRP6andLRP5play
redundant roles in regulating this process [46]. These possi-
bilities are being actively examined by several laboratories.
4. Linkageof LRP5 Mutationsto
Conditions withAlteredBone Mass
During the early part of this past decade, several reports
linked changes in bone mass to alterations in LRP5. The ﬁrst
report found that patients with osteoporosis pseudoglioma
syndrome (OPPG), an autosomal recessive disorder in which
aﬄicted individuals develop severe, early-onset osteoporosis
[47], are homozygous for inactivating mutations in LRP5
[48]. These individuals have a very high susceptibility to
multiple fractures and have severe deﬁcits in vision due to
persistence of the hyaloid vasculature often associated with
retinal detachment [47]. Shortly after loss of LRP5 function
was linked to OPPG, two groups independently reported
that families with extremely high bone mass (HBM) carried
a speciﬁc point mutation (G171V) in LRP5 [49, 50]. The
LRP5-G171V protein can no longer be bound by several
proteins (such as Dkk1, Sost, and MESD) that may normally
regulate its activity. Subsequently, work in mouse models by
several laboratories provided further conﬁrmation for a role
of Lrp5 in regulating bone mass [30, 46, 51–56].
LRP5isamemberofamultigenefamilyandseveralother
members of this family have shown to be involved in bone
development and disease. For example, mutations in LRP6,
whichsharesgreaterthan70% identity withLRP5,havebeen
linkedtochangesinbonemassinbothhumansandmice[28,
30, 53, 56, 57]. In addition, it has recently been shown that
LRP4, which is expressed in bone and cultured osteoblasts,
binds Dkk1 and sclerostin in vitro and that Lrp4-deﬁcient
mice revealed shortened total femur length, reduced cortical
femoralperimeter,reducedtotalfemurbonemineralcontent
(BMC), and bone mineral density (BMD) [58]. Thus, Lrp4
is also an osteoblast-expressed Dkk1- and sclerostin-receptor
with a physiological role in the regulation of bone growth
and turnover.
While it is important to note that some HBM patients
develop pain neurologic sequelae [59], the fact that these
patients do not appear to have an obvious predisposition
to cancer or other disease has led to several biotechnology
and pharmaceutical companies investing large amounts of
resources in developing agents in an attempt to mimic the
eﬀects of the LRP5 mutations associated with HBM [60].
Since the canonical Wnt pathway is ubiquitous in embryonic
development and oncogenesis [7], targeting LRP4-6 directly
may have unintended eﬀects. For example, both Lrp4
and Lrp6-deﬁcient mice exhibit signiﬁcant developmental
deformities [28, 33]. However, by concentrating on agonists
or antagonists speciﬁc to bone, we may signiﬁcantly reduce
those risks. Here, we focus on two groups of agents; those
designedtoinhibitthefunctionofSclerostinandthosewhich
block the activity of the DKK1 protein. Further, we brieﬂy
discuss sFRPs, whose aﬀects on bone are only recently being
reported.4 Journal of Osteoporosis
5. Sclerosteosisand Van Buchem’s Disease
Sclerosteosis is autosomal recessive disorder characterized
by progressive skeletal overgrowth [61, 62]. Patients appear
normal at birth, with the exception of some instances of syn-
dactyly. Skeletal overgrowth, especially in the mandible and
skull, commences early in life. This can cause compression of
the 7th and 8th cranial nerves often resulting in facial palsy
and conductive hearing loss.
In 2001, it was reported that a gene located on Chro-
mosome 17q11.2 was mutated in sclerosteosis [63, 64]. This
gene which encodes a secreted glycoprotein (Sclerostin or
Sost) containing a cysteine knot-like domain with homology
to the Cerebrus/DAN family of BMP antagonists [63, 64].
Subsequent work on a related disorder, Van Buchem’s Dis-
ease, revealed that while there was no mutation in the coding
region of the SOST gene, a homozygous 52 kB deletion in
a region closely linked to the SOST gene was identiﬁed in
these patients [65–67]. Patients with Van Buchem’s display
whatisessentiallyamilderversionofthesymptomsobserved
in Sclerosteosis. Additional work suggests that this deletion
results in downregulation of Sost expression [65–67].
Partly due to its homology to Cerberus and DAN family
members, it was originally thought that loss of Sost lead
to bone abnormalities primarily due to ectopic activation
of BMP pathways [68, 69]. However, subsequent work
demonstrated that it also bound Lrp5 and Lrp6 and could
prevent their interaction with Wnts [17–19]. Thus, loss of
Sost may lead to an inability to inactivate the Wnt signaling
pathway. Consistent with the skeletal overgrowth seen in
patients carrying the G171V mutation in LRP5, Sost is
unable to interact with the mutated version of LRP5 [70, 71].
A key characteristic that makes Sost a particularly
attractive target for the treatment of osteoporosis is that its
expression is restricted to osteocytes [72]. Thus, unintended
sideeﬀectscausedbyblockingactivityofthisproteininother
tissues are less likely. Furthermore, genetically engineered
mouse models designed to mimic the mutations seen in
Sclerosteosis and van Buchem’s patients accurately model
the high bone mass changes seen in humans [73].
Based on these characteristics, several pharmaceutical
companies have initiated programs to create biological
agents that inhibit Sost activity. Amgen, Novartis, and Eli
Lilly have all been reported to have developed monoclonal
antibodiesdesignedtoinhibitSOST[74].Inaddition,Osteo-
GeneX has reportedly developed a small molecule inhibitor
of SOST that is in the preclinical development stage [74].
Evidence for the potential eﬃcacy of such approaches
has been found in at least two preclinical models. Amgen
reported that an antibody that blocked SOST function
increased bone formation, bone strength, and bone mass in
a rat model of postmenopausal osteoporosis [75]. Further-
more, a similar antibody was reported to inhibit bone loss in
a mouse model of chronic colitis [76].
6. Dickkopf 1
D i c k k o p f 1( D K K 1 )i st h ep r o t o t y p eo fa4m e m b e rg e n e
family and was ﬁrst identiﬁed in 1998 [77]. Dkk proteins
contain two cysteine-rich domains. The more N-terminal
domain is Dkk-family speciﬁc, while the second domain
contains structural homology to the colipase fold [77]. At
that time, it was reported to be a secreted protein that
inhibited Wnt signal transduction, but did not bind directly
to Wnt proteins.
AfterLRP5andLRP6wereidentiﬁedasputativecorecep-
torsforWntligands[28,78,79],severalgroupsreportedthat
Dkk1 inhibited Wnt/β-catenin signaling via binding directly
to LRP5 and LRP6 and blocked the ability of Wnt ligands
to interact with LRP5 and LRP6 [80–82]. In addition, some
reports (but not all [71]) found that the version of the LRP5
protein found in HBM families (G171V) could not bind to
or be inhibited by DKK1 [83, 84]. Subsequent work showed
thatthreemembersofthisfamily(DKK1,DKK2,andDKK4)
were inhibitors of the Wnt/β-catenin pathway, while DKK3
was divergent in both function and structure [77].
Mouse models have provided further support for a key
role for Dkk1 in bone development. Germline deﬁciency
for Dkk1 results in embryonic lethality associated with
absence of head structures anterior to the midbrain and
abnormalities of digits in the limbs [85]. Studies of mice
heterozygous for an inactivating mutation in Dkk1 show
high bone mass associated with a signiﬁcant increase in the
bone formation rate [86]. In addition, heterozygosity for
a hypomorphic allele of Dkk1 (doubleridge) also results in
increased bone mass [87].
Based on these observations, several companies are
pursuing therapeutic approaches for bone disease based
on inactivating Dkk1 function. These include Nuvelo’s
development of a monoclonal antibody against Dkk1 and
a small molecule inhibitor approach being pursued by
Enzo Biochem [74]. To our knowledge, there has not
been published evidence for eﬃcacy studies in the area of
osteoporosis. However, several studies have found anti-Dkk1
antibodies were eﬀective in treating disease on preclinical
modeling systems. For example, administration of such
an antibody immediately following a fracture signiﬁcantly
enhanced bone repair [88]. There are also several examples
of anti-Dkk1 antibodies modulating the severity of diseases
such as multiple myeloma and osteoarthritis [89–91].
7.SecretedFrizzledRelatedProteins
Secreted frizzled related proteins are similar to DKK1 and
Sclerostin in that they also inhibit Wnt/β-catenin signaling.
However, they do so through a diﬀerent molecular mech-
anism. sFRPs inhibit canonical Wnt signaling by binding
directly to the Wnt molecule itself [92, 93]. sFRPs share
sequence similarity with the cysteine-rich domain (CRD)
found in the extracellular region of frizzled. sFRPs bind the
Wnt ligands through their CRD, thereby preventing their
binding to Frizzled receptors [94]. Results related to the
eﬀects of sFRPs are fairly recent. To date, sFRP-1 has been
shown to be involved in the anabolic aﬀects of PTH; deletion
of sFRP-1 resulted in increased trabecular bone mineral
density in a mouse model [95, 96]. Furthermore, sFRP-2 has
been shown to inhibit bone formation [97]. It should be
noted, though, that down regulation of sFRP-1 predisposesJournal of Osteoporosis 5
the mammary gland to tumorigenesis [98] while sFRP-2
is signiﬁcantly downregulated in gastric cancer [99], and
downregulation of both sFRP-1 and sFRP-2 contributes to
cervicalcancerprogression[100].Thus,approachesaimedat
inactivating sFRP function [95, 101, 102] should be pursued
with appropriate caution. Similar risks exist with DKK1
[103] and Sclerostin [104]. However, research to date has
not shown any predisposition of treatments utilizing these
molecules toward oncogenesis (see below).
8. FutureDirections
Preclinical studies with agents designed to block the func-
tions of Sost and DKK1 have shown promise in treating
bone disease and will likely be soon entering human clinical
trials for the treatment of osteoporosis. Ongoing work
will undoubtedly identify other potential druggable targets
within this pathway. For example, the ﬁnding that the
Prorenin receptor acts as an rennin-independent adaptor
between LRP6 (and potentially LRP5) and the vacuolar H+–
adenosine triphosphatase (V-ATPase) complex may provide
new drug targets [105]. The subsequent acidiﬁcation of
this compartment is required for phosphorylation of the
cytoplasmic tail of LRP6, which is necessary for activating
the downstream signaling cascade [106–108]. One could
envision approaches designed to enhance this event to
increase Wnt signaling and bone mass.
In addition to the development of agents directly tar-
geting components of this pathway, several current and
potential treatments for low bone mass may interact with
theWntsignalingpathway.Forexample,theanabolicactions
of Parathyroid hormone (the basis for Forteo/teriparatide
[109]) have been proposed to directly and/or indirectly
work through regulation of LRP6 and/or LRP5 signaling
[110–112]. In addition, osteoprotegerin (OPG), a molecule
produced by cells of the osteoblast lineage that inhibits
activation of osteoclasts [113], is a direct transcriptional
target for β-catenin [44, 45]. Denosumab, a monoclonal
antibodyinclinicaltrialsdevelopedbyAmgen[114],isbased
on the function of OPG. However, while the regulation is
clearly altered in mice carrying mutations which directly
activate or inactivate β-catenin, it does not appear to be
alteredinmiceorhumanscarryinginactivatingmutationsin
LRP5 [48,51].Thisdemonstratesthepotentialcomplexityof
regulationwithinthesepathways,andemphasizesthecritical
needto increaseourknowledge aboutthedetailed regulation
of Wnt signaling pathways within osteoblasts.
Activation of the Wnt signaling pathway is one of the
mostcommoneventsassociatedwithhumancancer[7,115].
As previously noted, the potential for treatments aimed at
activating the Wnt signaling pathway to increase bone mass
must always been tempered by consideration of a potentially
increasedsusceptibilitytocarcinogenesisorotherdeleterious
consequences. However, several observations suggest that
this may not be as large a concern in the context of treating
bone disease as some originally feared. First, neither the
LRP5HBMpatientsnorthosewithSclerosteosisarereported
to have an increased rate of carcinogenesis. In addition,
there have been no reports in the preclinical modeling
studies of increased carcinogenesis in mice treated with
agents that block Dkk1 or Sost. Finally, lithium chloride
has been used for decades to treat psychiatric illnesses in
humans without being associated with any apparent increase
in cancer risk. Given that the main mechanism of action for
lithium treatment is inhibition of GSK3 activity (associated
withupregulationofβ-cateninsignaling)[116],thisprovides
further conﬁdence in the approaches discussed in this paper.
Some concerns should also exist regarding the eﬀects
of systemic upregulation of Wnt/β-catenin signaling on
fracture healing. While it is presumable that eﬃcacy of
these drugs would reduce fragility fractures in osteoporotic
patients, the likelihood of fracture due to moving vehicle
accidents or other misfortune is not necessarily reduced.
Therefore, the eﬀects of potential drugs on healing cannot be
ignored. Unfortunately, the role of Wnt/β-catenin signaling
in fracture healing is only beginning to be understood and
therefore could lead to diﬃculties. Forexample, nonsteroidal
antiinﬂammatorydrugs(NSAIDs)thatinhibitinﬂammatory
response through down regulation of Cox2 were expected to
have little eﬀect on bone healing since mice lacking Cox2
form normal skeletons. However, it was later shown that
fracture healing failed in rats treated with COX-2–selective
NSAIDs and consequently, it was concluded that COX-2
function is speciﬁcally essential for fracture healing but not
embryonic skeletal development [117]. Early indications are
that Wnt signaling is both upregulated and downregulated
temporally throughout the healing process [118]. As such,
regulation of canonical Wnt signaling during this process is
presentlyunpredictable.Furtherinvestigationintotheroleof
canonical Wnt signaling in fracture healing is required.
In summary, the discovery almost a decade ago that
mutations in LRP5 were causally associated with alterations
in bone mass has stimulated numerous lines of research
that have identiﬁed a number of promising targets to treat
osteoporosis. The next decade will undoubtedly see the
further translation of these ﬁndings into clinical use.
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